润都股份：盐酸去甲乌药碱注射液目前审评状态变更为暂停，但整体仍处于审评阶段

Core Points - The company, Rundu Co., Ltd. (002923.SZ), announced on November 28 that the share reduction by its common actual controller, Mr. Li Xi, is based on personal funding needs and has complied with relevant regulations regarding information disclosure [2] Group 1: Shareholder Actions - The share reduction by Mr. Li Xi has been conducted in accordance with the "Interim Measures for the Administration of Share Reduction by Shareholders of Listed Companies" [2] - The company has disclosed the details of the share reduction in its announcement on the Giant Tide Information Network [2] Group 2: Regulatory Compliance - The company is adhering to the "Regulations on the Suspension and Resumption of Review Time in the Drug Review Process" issued by the National Medical Products Administration [2] - The review status of the drug, Sodium Deoxycorticosterone Injection, has been changed to suspended, but it remains in the review phase, which is considered normal [2] Group 3: Future Disclosure - The company commits to timely information disclosure in case of any significant developments regarding the drug review process [2]